SPIN-OFF PARENT MAIN INVESTORS/AMOUNT SPECIALTY

ADDEX GlaxoSmithKline Index Ventures and Soffinova Anti-addiction & Roche Holdings Partners/$9.9 million drugs

BIOVITRUM Pharmacia MPM Capital and Nordic Metabolic Capital/$130 million diseases

BIOXELL Roche MPM Capital and Index Immunology Ventures/$22 million

PROSKELIA Aventis Warburg Pincus/$60 million Bone research

METAGEN Schering AG Apax/$42 million Cancer

Data: Company reports

Before it's here, it's on the Bloomberg Terminal. LEARN MORE